MEDICINOVA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
MEDICINOVA, INC. (MNOV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.97 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.99, a 27.21% decline year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.36, a 36.00% increase year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.00, a 37.50% decline year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.60, a 10.34% increase year-over-year.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.34, a 35.35% increase from fiscal 2024.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $0.99, a 37.74% decline from fiscal 2023.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.59, a 8.16% increase from fiscal 2022.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.47, a 58.12% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.97 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $0.99 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $1.34 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $1.34 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.34 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $1.36 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $0.99 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $0.99 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $0.99 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $1.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $1.59 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $1.60 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $1.60 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.60 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $1.47 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $1.47 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $1.47 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $1.45 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $3.51 10-K/A · filed 2023-03-28 | |||
| 2021-09-30 | $3.33 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $3.52 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $3.59 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $3.70 10-K · filed 2022-02-16 | |||
| 2019-12-31 | $2.76 10-K · filed 2021-02-19 | |||
| 2018-12-31 | $4.57 10-K · filed 2020-02-13 | |||
| 2017-12-31 | $3.78 10-K · filed 2019-02-13 | |||
| 2016-12-31 | $2.64 10-K · filed 2019-02-13 | |||
| 2015-12-31 | $2.08 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $1.58 10-K · filed 2017-02-14 | |||
| 2013-12-31 | $2.37 10-K · filed 2015-03-12 | |||
| 2012-12-31 | $1.33 10-K · filed 2014-03-27 | |||
| 2011-12-31 | $1.25 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |